SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending amid community discussion around its potential as 'the new Bitcoin' and increased institutional interest, particularly following investments from figures like the Winklevoss twins. Conversations highlight ZEC's privacy features and limited supply, with some suggesting a significant shift from Bitcoin to Zcash. Bullish sentiment is tempered by concerns about volatility and potential corrections.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the crypto community discusses its potential breakout, referencing patterns observed in Zcash's previous run. Bullish sentiment is fueled by the anticipation of a government reopening and the LTCN ETF, with some eyeing price targets in the hundreds. Technical analysis chatter includes inverted head and shoulders patterns and golden cross formations, suggesting a possible surge if key resistance levels are breached.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst heightened speculation and community chatter surrounding the release of Epstein files and their potential implications for the company and its figureheads. The community is actively dissecting alleged connections and potential fallouts, while some voice concerns about the company's financial performance. Political narratives and partisan bickering continue to fuel the conversation around the stock.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending amid discussions about its partnership with Vaxart for an oral COVID-19 vaccine, a potential game-changer in vaccine delivery. The community is weighing the implications of institutional ownership, share buybacks, and a proxy fight involving Deep Track Capital. Some are speculating on potential buyout scenarios and the future direction of Dynavax's strategic partnerships.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending as investors discuss upcoming earnings and the company's potential for profitability, with some anticipating a positive report. Community members are also highlighting XPEV's expansion into robotics and AI, seeing it as more than just an EV company and comparing its progress to competitors. Bullish sentiment seems to be growing, although some concerns about cash flow and potential dilution remain.

The community has officially TAKEN OVER $HIPPO - after the dev threw in the towel! The cutest $HIPPO on SUI is now powered by a full CTO. No cats, no dogs. Only $HIPPO, driven by the people, for the people! $HIPPO is ready to break out stronger than ever!  Su Deng is the cutest $HIPPO on SUI, bringing $HIPPO to the world of memes.  $HIPPO - No cats, no dogs Only hippo!  We are donating a % of our profits to wildlife needs across the world. Starting with support for Khao Kheow Open Zoo, the zoo that houses Moo Deng

sudeng

HIPPO (sudeng) is experiencing increased attention, with community members actively discussing potential pumps and anticipating a comeback. The conversation includes speculation about market influences, recent price drops, and comparisons to other meme coins in the SUI ecosystem, generating both excitement and questions about its future.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amidst lowered sales guidance for 2025, despite a recent revenue beat and expansion of a U.S. Army contract, triggering debate about management's credibility and future prospects. Community discussions revolve around the impact of government delays and the potential for a strong 2026, with some expressing concerns about the company's leadership and others seeing a buying opportunity. The drone sector's overall growth potential remains a key talking point.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind (MNKD) is trending due to community discussion around the company's leadership and strategic decisions, particularly regarding CEO Mike Castagna. Debate centers on past agreements, product commercialization, and the potential for a merger or acquisition. Bullish sentiment exists based on analyst upgrades and future growth prospects, while others express concerns about the company's performance and direction.

Tidal Trust II - YieldMax TSLA Option Income Strategy ETF

YieldMax TSLA Option Income Strategy ETF

TSLY is trending due to news of a potential reverse split, leading to discussions about its impact on the ETF and investor returns. Community members are also weighing in on recent dividend payouts and strategizing around reinvestment and potential trading opportunities. Some are expressing concerns about NAV erosion and comparing TSLY to other high-yield ETFs.

Matador Resources Co. is a holding company, which engages in the exploration, development, production, and acquisition of oil and natural gas resources. It operates through the following segments: Exploration and Production, Midstream, and Corporate. The Exploration and Production segment focuses on the exploration, development, production, and acquisition of oil and liquids-rich portion of the Wolfcamp and Bone Spring. The Midstream segment conducts natural gas processing, oil transportation services, oil, natural gas and produced water gathering services, and produced water disposal services to third parties. The company was founded by Joseph William Foran and Scott E. King in July 2003 and is headquartered in Dallas, TX.

Matador Resources Co

Matador Resources is trending as investors discuss its potential as an acquisition target, citing its strong free cash flow yield and low valuation. Community members are also weighing MTDR against other energy companies, while noting recent insider buying activity. Technical analysis suggests a neutral to bullish outlook, with some traders outlining potential entry and exit points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cantor Fitzgerald Issues Positive Forecast for CRVS Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2026 EPS estimates for Corvus Pharmaceuticals in a research note issued to...

What is HC Wainwright's Estimate for CRVS FY2025 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright upped their FY2025 EPS estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, November 5th...

Wall Street Zen Upgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to "Hold"

Wall Street Zen raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...

HC Wainwright Has Bearish Forecast for CRVS FY2028 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are covering the stock...

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...

Shares of Corvus Pharmaceuticals, Inc. (CRVS) traded 30% higher on Friday afternoon after Oppenheimer raised its price target on the stock to $17 from $15, while keeping an ‘Outperform’ rating on the stock.The brokerage cited <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-data-cohorts-1-3-placebo">positive</a> results from a clinical trial announced by the company on Thursday, as per TheFly. Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.The data demonstrated a favorable safety and efficacy profile, particularly in cohort 3, where patients received higher doses of 200 mg twice daily, the company said.The update continues to support Oppenheimer's enthusiasm for the candidate in this potential blockbuster indication. The firm views these data as highly competitive with Dupilumab and other systemic options for patients with atopic dermatitis.Oppenheimer’s new price target implies a 407% upside to the stock’s closing price of $3.35 on Thursday.Corvus on Thursday reported a first-quarter loss of $0.13 per share, marginally higher than the loss of $0.12 reported in the corresponding period of 2024, and above an estimated loss of $0.12, as per Finchat data.The company ended the quarter with cash, cash equivalents, and marketable securities of $44.2 million compared to $52.0 million as of Dec. 31, 2024, which it expects will fund operations into the fourth quarter of 2026.On Stocktwits, retail sentiment around Corvus rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_12_10_36_PM_png_c210c7fe04.webp" alt="CRVS's Sentiment Meter and Message Volume as of 12:10 p.m. ET on May 9, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>CRVS's Sentiment Meter and Message Volume as of 12:10 p.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CRVS">CRVS stock</a> is down by about 20% this year but up by about 115% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/inspiremd-reports-wider-than-expected-q1-loss/chiWwLoRblh">InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.

Equity

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.


Shares of Corvus Pharmaceuticals, Inc., fell in Tuesday's extended trading hours after the company posted financial results below Wall Street expectations, although retail traders remained optimistic.The pre-revenue biotech posted an adjusted fourth-quarter (Q4) loss of $0.18 per share, steeper than the expected $0.12 loss.&nbsp;Research and development expenses in the reported quarter rose to $6 million from $4 million a year earlier, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.R&amp;D expenses climbed to $19.4 million for the full year from $16.5 million in 2023."We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases," said CEO Richard Miller.Preclinical data supports its potential in a range of conditions, including solid tumors, autoimmune disorders such as ALPS and systemic sclerosis, as well as inflammatory diseases like asthma and psoriasis.Corvus is nearing complete enrollment in the third cohort of its Phase 1 atopic dermatitis trial, while its Phase 3 trial in peripheral T-cell lymphoma (PTCL) is enrolling patients across multiple sites.&nbsp;The company recently launched a Phase 2 trial for ALPS and plans to initiate a solid tumor study in the third quarter of 2025.As of Dec. 31, 2024, Corvus held $52 million in cash, cash equivalents, and marketable securities, up from $27.1 million a year ago, which it expects to fund operations into the first quarter of 2026.On Stocktwits, sentiment for Corvus flipped into 'extremely bullish' territory from 'bearish' a day ago, accompanied by a 1,000% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CRVS_sentiment_and_message_volume_as_of_March_25_png_2347150685.webp" alt="CRVS sentiment and message volume as of March 25.png" width="1318" height="302"><figcaption>CRVS sentiment and message volume as of March 25. | source: Stocktwits</figcaption></figure>One user was bullish after the company's chief executive said the full data for the first three cohorts of its atopic dermatitis trial would be presented at the Society for Investigative Dermatology (SID) Annual Meeting in San Diego in May.<stembedurl>https://stocktwits.com/WalterBean/message/609216709</stembedurl>Another retail watcher expects the stock to close above $4 on Wednesday.<stembedurl>https://stocktwits.com/tradingjunk321/message/609231445</stembedurl>Corvus stock is down more than 28% this year but has more than doubled over the past 12 months. According to Koyfin, out of the six analysts covering the stock on Wall Street, five rate it 'buy' and one rates it 'strong buy.'For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) (Corvus) on behalf of the companys shareholders. The investigation seeks to determine whether Corvus...

Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday...

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc